Related Experiment Video

Updated: Aug 14, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Treatment of anicteric acute hepatitis C with peginterferon alpha-2a plus ribavirin

Dragan Delić1, Zorica Nesić, Milica Prostran

  • 1Clinical Center of Serbia, Institute of Infectious and Tropical Diseases, Belgrade. ddelic@mail.com

Vojnosanitetski Pregled
|December 27, 2005
PubMed

Insights

A single patient with acute Hepatitis C virus (HCV) infection achieved a stable virological response after 24 weeks of combination therapy with pegylated interferon-alpha 2a and ribavirin. Further studies are needed to confirm this treatment approach for acute HCV.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection frequently leads to chronic liver disease, cirrhosis, and hepatocellular carcinoma.
  • Acute hepatitis C often progresses to chronic infection, with spontaneous recovery in only 15-30% of cases.
  • Optimal treatment for acute HCV remains undetermined due to its rarity and unpredictable presentation.

Observation:

  • A patient with anicteric acute hepatitis C was treated with a combination therapy regimen.
  • The treatment consisted of pegylated interferon-alpha 2a (180 mcg weekly) and ribavirin (1000 mg daily) for 24 weeks.
  • The patient was monitored for three months prior to treatment initiation.

Findings:

  • The patient achieved a stable biochemical and virological response.
  • This response was sustained at the end of the 24-week treatment period.
  • The positive outcome persisted for at least 6 months post-therapy completion.

Implications:

  • This case suggests a potential therapeutic strategy for acute Hepatitis C virus infection.
  • Combination therapy with pegylated interferon-alpha 2a and ribavirin may prevent chronic HCV development.
  • Larger prospective studies are essential to validate these findings and establish definitive treatment guidelines for acute HCV.
Abstract

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...